Abstract
Background and Aim: Repetitive transcranial magnetic stimulation (rTMS) is supposed to be not as effective in severe depression as it is in medium depression. We evaluated the treatment response to an ultra-high-frequency (UHF; 30 Hz) approach, which was used to maximize the rTMS efficacy in severely ill patients. Methods: 43 severely depressed patients were included in the randomized, double-blind study and received either rTMS with 30 Hz over the left dorsolateral prefrontal cortex or sham condition for 3 weeks as an add-on therapy to stable antidepressant medication. Hamilton Depression Rating Scale (HDRS) and cognitive performance were evaluated before and after the intervention. Results: In the active UHF group, the HRDS score was reduced by about 7.2, whereas the sham condition showed a smaller reduction of the HDRS score with 3.9. However, lithium as a covariant was responsible for the outcome difference, not the group of stimulation. No adverse events were reported. Comparing the differences of both groups in the pre- and post-study performance in a trail-making test, a group effect for the UHF group that was not influenced by the lithium intake was observed. Conclusion: A 30-Hz left prefrontal rTMS in severely depressed patients was safe and no adverse events occurred. Due to a strong effect of lithium as a covariate, we could not demonstrate favorable antidepressant effects of the UHF stimulation compared to sham. However, we found an improvement of processing speed performance in the UHF group, which covaried with improvement of psychomotor retardation.
References
1.
Pascual-Leone A, Rubio B, Pallardo F, Catala MD: Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 1996;348:233–237.
2.
O’Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA: Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007;62:1208–1216.
3.
George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA: Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010;67:507–516.
4.
Eschweiler GW, Wegerer C, Schlotter W, Spandl C, Stevens A, Bartels M, Buchkremer G: Left prefrontal activation predicts therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) in major depression. Psychiatry Res 2000;99:161–172.
5.
Jorge RE, Robinson RG, Tateno A, Narushima K, Acion L, Moser D, Arndt S, Chemerinski E: Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. Biol Psychiatry 2004;55:398–405.
6.
Rumi DO, Gattaz WF, Rigonatti SP, Rosa MA, Fregni F, Rosa MO, Mansur C, Myczkowski ML, Moreno RA, Marcolin MA: Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry 2005;57:162–166.
7.
Rossini D, Lucca A, Zanardi R, Magri L, Smeraldi E: Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res 2005;137:1–10.
8.
Nahas Z, Kozel FA, Li X, Anderson B, George MS: Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. Bipolar Disord 2003;5:40–47.
9.
Loo C, Mitchell P, Sachdev P, McDarmont B, Parker G, Gandevia S: Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am J Psychiatry 1999;156:946–948.
10.
Hoppner J, Schulz M, Irmisch G, Mau R, Schlafke D, Richter J: Antidepressant efficacy of two different rTMS procedures. High frequency over left versus low frequency over right prefrontal cortex compared with sham stimulation. Eur Arch Psychiatry Clin Neurosci 2003;253:103–109.
11.
Poulet E, Brunelin J, Boeuve C, Lerond J, D’Amato T, Dalery J, Saoud M: Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. Eur Psychiatry 2004;19:382–383.
12.
Miniussi C, Bonato C, Bignotti S, Gazzoli A, Gennarelli M, Pasqualetti P, Tura GB, Ventriglia M, Rossini PM: Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression? Clin Neurophysiol 2005;116:1062–1071.
13.
Schutter DJ: Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: A meta-analysis. Psychol Med 2009;39:65–75.
14.
Holtzheimer PE 3rd, Russo J, Avery DH: A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. Psychopharmacol Bull 2001;35:149–169.
15.
Martin JL, Barbanoj MJ, Schlaepfer TE, Thompson E, Perez V, Kulisevsky J: Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis. Br J Psychiatry 2003;182:480–491.
16.
Couturier JL: Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis. J Psychiatry Neurosci 2005;30:83–90.
17.
Slotema CW, Blom JD, Hoek HW, Sommer IE: Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 2010;71:873–884.
18.
Wassermann EM: Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the international workshop on the safety of repetitive transcranial magnetic stimulation, June 5–7, 1996. Electroencephalogr Clin Neurophysiol 1998;108:1–16.
19.
Rossi S, Hallett M, Rossini PM, Pascual-Leone A: Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009;120:2008–2039.
20.
Zyss T, Mamczarz J, Vetulani J: The influence of rapid-rate transcranial magnetic stimulation (rTMS) parameters on rTMS effects in porsolt’s forced swimming test. Int J Neuropsychopharmacol 1999;2:31–34.
21.
Oswald WD, Roth E: Der Zahlen-Verbindungs-Test (ZVT). Göttingen, Hogrefe, 1987.
22.
Erzigkeit H: The SKT – a short cognitive performance test as an instrument for the assessment of clinical efficacy of cognition enhancers; in Bergener M, Reisberg B (eds): Diagnosis and Treatment of Senile Dementia. Berlin, Springer, 1989, pp 164–174.
23.
Herwig U, Satrapi P, Schonfeldt-Lecuona C: Using the international 10–20 EEG system for positioning of transcranial magnetic stimulation. Brain Topogr 2003;16:95–99.
24.
Kasper S, Zivkov M, Roes KC, Pols AG: Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol 1997;7:115–124.
25.
Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ: Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005;19:137–146.
26.
Eranti S, Mogg A, Pluck G, Landau S, Purvis R, Brown RG, Howard R, Knapp M, Philpot M, Rabe-Hesketh S, Romeo R, Rothwell J, Edwards D, McLoughlin DM: A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. Am J Psychiatry 2007;164:73–81.
27.
George MS, Post RM: Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression. Am J Psychiatry 2011;168:356–364.
28.
Sachdev PS, McBride R, Loo C, Mitchell PM, Malhi GS, Croker V: Effects of different frequencies of transcranial magnetic stimulation (TMS) on the forced swim test model of depression in rats. Biol Psychiatry 2002;51:474–479.
29.
Benninger DH, Lomarev M, Wassermann EM, Lopez G, Houdayer E, Fasano RE, Dang N, Hallett M: Safety study of 50 Hz repetitive transcranial magnetic stimulation in patients with Parkinson’s disease. Clin Neurophysiol 2009;120:809–815.
30.
Triggs WJ, Ricciuti N, Ward HE, Cheng J, Bowers D, Goodman WK, Kluger BM, Nadeau SE: Right and left dorsolateral pre-frontal rTMS treatment of refractory depression: a randomized, sham-controlled trial. Psychiatry Res 2010;178:467–474.
31.
Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F: Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One 2009;4:e4824.
32.
Herwig U, Fallgatter AJ, Hoppner J, Eschweiler GW, Kron M, Hajak G, Padberg F, Naderi-Heiden A, Abler B, Eichhammer P, Grossheinrich N, Hay B, Kammer T, Langguth B, Laske C, Plewnia C, Richter MM, Schulz M, Unterecker S, Zinke A, Spitzer M, Schonfeldt-Lecuona C: Antidepressant effects of augmentative transcranial magnetic stimulation: randomised multicentre trial. Br J Psychiatry 2007;191:441–448.
33.
Berlim MT, McGirr A, Beaulieu MM, Turecki G: High frequency repetitive transcranial magnetic stimulation as an augmenting strategy in severe treatment-resistant major depression: a prospective 4-week naturalistic trial. J Affect Disord 2010;130:312–317.
34.
Ray S, Nizamie SH, Akhtar S, Praharaj SK, Mishra BR, Zia-ul-Haq M: Efficacy of adjunctive high frequency repetitive transcranial magnetic stimulation of left prefrontal cortex in depression: a randomized sham controlled study. J Affect Disord 2010;128:153–159.
35.
Berlim MT, Turecki G: What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol 2007;17:696–707.
36.
Kaptchuk TJ, Goldman P, Stone DA, Stason WB: Do medical devices have enhanced placebo effects? J Clin Epidemiol 2000;53:786–792.
37.
Fava M: Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649–659.
38.
Fitzgerald PB, Benitez J, de Castella A, Daskalakis ZJ, Brown TL, Kulkarni J: A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am J Psychiatry 2006;163:88–94.
39.
Loo CK, Sachdev PS, Haindl W, Wen W, Mitchell PB, Croker VM, Malhi GS: High (15 Hz) and low (1 Hz) frequency transcranial magnetic stimulation have different acute effects on regional cerebral blood flow in depressed patients. Psychol Med 2003;33:997–1006.
40.
Loo CK, Taylor JL, Gandevia SC, McDarmont BN, Mitchell PB, Sachdev PS: Transcranial magnetic stimulation (TMS) in controlled treatment studies: are some ‘sham’ forms active? Biol Psychiatry 2000;47:325–331.
41.
Avery DH, Isenberg KE, Sampson SM, Janicak PG, Lisanby SH, Maixner DF, Loo C, Thase ME, Demitrack MA, George MS: Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry 2008;69:441–451.
42.
Loo CK, Mitchell PB: A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. J Affect Disord 2005;88:255–267.
43.
Mahlberg R, Adli M, Bschor T, Kienast T: Age effects on trail making test during acute depressive and manic episode. Int J Neurosci 2008;118:1347–1356.
44.
Ahmed MA, Darwish ES, Khedr EM, El Serogy YM, Ali AM: Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer’s dementia. J Neurol 2012;259:83–92.
45.
Pier MP, Hulstijn W, Sabbe BG: No psychomotor slowing in fine motor tasks in dysthymia. J Affect Disord 2004;83:109–120.
46.
Neu P, Kiesslinger U, Schlattmann P, Reischies FM: Time-related cognitive deficiency in four different types of depression. Psychiatry Res 2001;103:237–247.
47.
Baeken C, De Raedt R, Santermans L, Zeeuws D, Vanderhasselt MA, Meers M, Vanderbruggen N: HF-rTMS treatment decreases psychomotor retardation in medication-resistant melancholic depression. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:684–687.
48.
Padberg F, Zwanzger P, Keck ME, Kathmann N, Mikhaiel P, Ella R, Rupprecht P, Thoma H, Hampel H, Toschi N, Moller HJ: Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. Neuropsychopharmacology 2002;27:638–645.
49.
Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC: Theta burst stimulation of the human motor cortex. Neuron 2005;45:201–206.
50.
Grossheinrich N, Rau A, Pogarell O, Hennig-Fast K, Reinl M, Karch S, Dieler A, Leicht G, Mulert C, Sterr A, Padberg F: Theta burst stimulation of the prefrontal cortex: safety and impact on cognition, mood, and resting electroencephalogram. Biol Psychiatry 2009;65:778–784.
51.
Chistyakov AV, Rubicsek O, Kaplan B, Zaaroor M, Klein E: Safety, tolerability and preliminary evidence for antidepressant efficacy of theta-burst transcranial magnetic stimulation in patients with major depression. Int J Neuropsychopharmacol 2010;13:387–393.
52.
Holzer M, Padberg F: Intermittent theta burst stimulation (iTBS) ameliorates therapy-resistant depression: a case series. Brain Stimul 2010;3:181–183.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
